When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 24 Apr 2025
Last updated: 23 May 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • constitutional symptoms
  • dyspnoea
  • productive cough
  • dullness to percussion
  • diminished breath sounds
  • crackles
  • headache
  • alteration of consciousness
  • meningeal irritation
  • papilloedema
  • skin lesions
  • coma

Other diagnostic factors

  • chest pain
  • cranial neuropathy
  • ocular manifestations

Risk factors

  • HIV infection
  • immunosuppression
  • exposure to Cryptococcus species
  • male sex
  • pregnancy and postnatal period

Diagnostic investigations

1st investigations to order

  • serum cryptococcal polysaccharide antigen (CrAg)
  • cerebrospinal fluid (CSF) cryptococcal polysaccharide antigen (CrAg)
  • pleural fluid cryptococcal polysaccharide antigen (CrAg)
  • cultures
  • HIV antibodies
  • chest x-ray
  • lumbar puncture
  • cerebrospinal fluid (CSF) microscopy
  • cerebrospinal fluid (CSF) white blood cell count (cells/microlitre)

Investigations to consider

  • CT chest
  • MRI brain
  • CT brain
  • bronchoscopy
  • biopsy

Emerging tests

  • cryptococcus polymerase chain reaction (PCR)

Treatment algorithm

Contributors

Authors

Radha Rajasingham, MD

Associate Professor of Medicine

Infectious Diseases and International Medicine

Department of Medicine

University of Minnesota

Minneapolis

MN

Disclosures

RR receives grants from the US National Institutes of Health (NIH) for prevention of cryptococcal meningitis clinical trials. She is a consultant for the Pan American Health Organization for research in histoplasmosis screening. RR is an author of several references cited in this topic.

Acknowledgements

Dr Radha Rajasingham would like to gratefully acknowledge Dr David Boulware, Dr Renata L. Riha, and Dr Athanasia D. Pataka, previous contributors to this topic.

Disclosures

DRB has received research support from Gilead. RLR and ADP declare that they have no competing interests.

Peer reviewers

William Powderly, MD

Professor of Medicine

Washington University in St Louis

St Louis

MO

Disclosures

WP declares that he is a member of advisory boards for Gilead and Merck and his institution has received research grants from Merck; none of these are related to antifungal therapy. WP is a member of the Board of Directors (Past President) of the Infectious Diseases Society of America. WP is an author of a reference cited in this topic.

Ricardo Negroni, MD

Consultant

Muñiz Hospital

Honorary Professor

University of Buenos Aires

Buenos Aires

Argentina

Disclosures

RN declares that he has no competing interests.

Aimee Zaas, MD, MHS

Assistant Professor of Medicine

Division of Infectious Diseases and International Health

Duke University Medical Center

Durham

NC

Disclosures

AZ has received research funding from Enzon Pharmaceuticals and has been on the speaker's bureau for Astellas Pharma and Pfizer Inc.

Joseph Jarvis, BSc, MBBS, MRCP

Professor

Department of Clinical Research

Faculty of Infectious and Tropical Diseases

London School of Hygiene and Tropical Medicine

London

UK

Disclosures

JJ declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2006 Sep;20(3):507-44. Abstract

Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: cryptococcosis. Oct 2024 [internet publication].Full text

World Health Organization. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Jun 2022 [internet publication].Full text

Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291-322.Full text  Abstract

Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014 Jun 26;370(26):2487-98.Full text  Abstract

Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014 Dec 1;59(11):1607-14.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer